260 related articles for article (PubMed ID: 27804122)
21. Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens.
Blankenship JR; Singh N; Alexander BD; Heitman J
J Clin Microbiol; 2005 Jan; 43(1):464-7. PubMed ID: 15635017
[TBL] [Abstract][Full Text] [Related]
22. Activation of renal profibrotic TGFβ controlled signaling cascades by calcineurin and mTOR inhibitors.
Eberhardt W; Nasrullah U; Pfeilschifter J
Cell Signal; 2018 Dec; 52():1-11. PubMed ID: 30145216
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
[TBL] [Abstract][Full Text] [Related]
24. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
25. Tacrolimus causes a blockage of protein secretion which reinforces its immunosuppressive activity and also explains some of its toxic side-effects.
Rauch MC; San Martín A; Ojeda D; Quezada C; Salas M; Cárcamo JG; Yañez AJ; Slebe JC; Claude A
Transpl Immunol; 2009 Dec; 22(1-2):72-81. PubMed ID: 19628039
[TBL] [Abstract][Full Text] [Related]
26. Regulation of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus at concentrations that inhibit calcineurin activity and involving the transcription factor CREB.
Oetjen E; Grapentin D; Blume R; Seeger M; Krause D; Eggers A; Knepel W
Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):227-36. PubMed ID: 12644894
[TBL] [Abstract][Full Text] [Related]
27. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.
Zhang X; Ji L; Yang L; Tang X; Qin W
Int Urol Nephrol; 2016 May; 48(5):731-43. PubMed ID: 26781720
[TBL] [Abstract][Full Text] [Related]
28. Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents.
Pereira MJ; Palming J; Rizell M; Aureliano M; Carvalho E; Svensson MK; Eriksson JW
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1885-94. PubMed ID: 25004245
[TBL] [Abstract][Full Text] [Related]
29. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling.
Rodrigues-Diez R; González-Guerrero C; Ocaña-Salceda C; Rodrigues-Diez RR; Egido J; Ortiz A; Ruiz-Ortega M; Ramos AM
Sci Rep; 2016 Jun; 6():27915. PubMed ID: 27295076
[TBL] [Abstract][Full Text] [Related]
30. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
31. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
Bai JP; Lesko LJ; Burckart GJ
Pharmacotherapy; 2010 Feb; 30(2):195-209. PubMed ID: 20099993
[TBL] [Abstract][Full Text] [Related]
32. Calcineurin Inhibitors Downregulate HNF-1β and May Affect the Outcome of HNF1B Patients After Renal Transplantation.
Faguer S; Esposito L; Casemayou A; Pirson Y; Decramer S; Cartery C; Hazzan M; Garrigue V; Roussey G; Cointault O; Ho T; Merville P; Devuyst O; Gourdy P; Chassaing N; Bascands JL; Kamar N; Schanstra JP; Rostaing L; Chauveau D
Transplantation; 2016 Sep; 100(9):1970-8. PubMed ID: 26555949
[TBL] [Abstract][Full Text] [Related]
33. Adverse effects of immunosuppression after liver transplantation.
Noble J; Terrec F; Malvezzi P; Rostaing L
Best Pract Res Clin Gastroenterol; 2021; 54-55():101762. PubMed ID: 34874845
[TBL] [Abstract][Full Text] [Related]
34. Relationship between pharmacokinetics and pharmacodynamics of calcineurin inhibitors in renal transplant patients.
Albring A; Wendt L; Harz N; Engler H; Wilde B; Kribben A; Lindemann M; Schedlowski M; Witzke O
Clin Transplant; 2015 Apr; 29(4):294-300. PubMed ID: 25557538
[TBL] [Abstract][Full Text] [Related]
35. Anti-Diabetogenic Properties of Mineralocorticoid Receptor Antagonists: Implications for Enhanced Safety and Efficacy of Post-Transplantation Pharmacotherapies.
Ming Y; Stefano GB; Kream RM; Zhuang Q
Med Sci Monit; 2019 Feb; 25():1102-1104. PubMed ID: 30739121
[TBL] [Abstract][Full Text] [Related]
36. Complete reversal of FK 506 induced diabetes in a liver transplant recipient by change of immunosuppression to cyclosporine A.
Kanzler S; Lohse AW; Schirmacher P; Hermann E; Otto G; Meyer zum Büschenfelde KH
Z Gastroenterol; 1996 Feb; 34(2):128-31. PubMed ID: 8659188
[TBL] [Abstract][Full Text] [Related]
37. Diabetogenic effect of cyclosporin A is mediated by interference with mitochondrial function of pancreatic B-cells.
Düfer M; Krippeit-Drews P; Lembert N; Idahl LA; Drews G
Mol Pharmacol; 2001 Oct; 60(4):873-9. PubMed ID: 11562451
[TBL] [Abstract][Full Text] [Related]
38. Deciphering the mechanism of calcineurin inhibitor-induced hypertension.
Kortenoeven MLA
Acta Physiol (Oxf); 2023 Jun; 238(2):e13976. PubMed ID: 37043175
[No Abstract] [Full Text] [Related]
39. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.
Vanhove T; Annaert P; Kuypers DR
Drug Metab Rev; 2016; 48(1):88-112. PubMed ID: 26912097
[TBL] [Abstract][Full Text] [Related]
40. [Controversies about the use of calcineurin inhibitors in pediatric patients].
Dello Strologo L
G Ital Nefrol; 2008; 25(3):317-24. PubMed ID: 18473303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
